Corvus Pharmaceuticals, Inc. (CRVS) Net income 2016–2025
Corvus Pharmaceuticals, Inc. (CRVS) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$15.3MFY2025 · since FY2016: -$36.4M → -$15.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$15.3M | +75.5% |
| FY2024 | -$62.3M | -130.5% |
| FY2023 | -$27.0M | +34.6% |
| FY2022 | -$41.3M | +4.5% |
| FY2021 | -$43.2M | -621.3% |
| FY2020 | -$6.0M | +87.2% |
| FY2019 | -$46.7M | +0.6% |
| FY2018 | -$46.9M | +15.7% |
| FY2017 | -$55.7M | -53.0% |
| FY2016 | -$36.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More CRVS financial trends
CRVS RevenueCRVS Net marginCRVS Gross profitCRVS Gross marginCRVS Operating incomeCRVS Operating marginCRVS Operating cash flowCRVS Free cash flowCRVS Capital expendituresCRVS Return on equityCRVS Stock buybacksCRVS Dividends paidCRVS Total assetsCRVS Total liabilitiesCRVS Shareholders’ equityCRVS overview →